

# **BALANCED BLUE SPECTRUM** **THERAPY LIGHTING**

Patent Application  
of

**Charles Bolta**  
**625 Mathews Street**  
**Ft. Collins, Colorado 80524**

Attorney

**Emery L. Tracy**  
**Reg. No. 34,081**  
**P.O. Box 1518**  
**Boulder, Colorado 80306-1518**  
**Telephone: 303-443-1143**  
**Facsimile: 303-443-1415**

Docket No.: B012.PAT-2

## BALANCED BLUE SPECTRUM THERAPY LIGHTING

1           The present application is a continuation of pending provisional patent application  
2       Serial No. 60/420,624, filed on October 23, 2002, entitled "Balanced Blue Spectrum  
3       Therapy Lighting".

### 4 5       BACKGROUND OF THE INVENTION

#### 6       1.     Field of the Invention

7           This invention relates generally to therapy lighting and, more particularly, the  
8       invention relates to balanced blue spectrum therapy lighting for regulating melatonin.

#### 9 10      2.    Description of the Prior Art

11          Although receptive field sizes account for some of the differences in visual  
12       sensitivity across the retina, the sensitivity at a given retinal location can also vary. The  
13       human eye can process information over an enormous range of luminance (about twelve  
14       (12) log units). The visual system changes its sensitivity to light; a process called  
15       adaptation, so that it may detect the faintest signal on a dark night and yet not be  
16       overloaded by the high brightness of a summer beach scene. Adaptation involves four  
17       major processes:

18          1. *Changes in Pupil Size.* The iris constricts and dilates in response to increased  
19       and decreased levels of retinal illumination. Iris constriction has a shorter latency and is  
20       faster (about 0.3 s) than dilation (about 1.5 s). There are wide variations in pupil sizes  
21       among individuals and for a particular individual at different times. Thus, for a given  
22       luminous stimulus, some uncertainty is associated with an individual's pupil size unless it  
23       is measured. In general, however, the range in pupil diameter for young people may be  
24       considered to be from two (2) mm for high levels to eight (8) mm for low levels of retinal  
25       illumination. This change in pupil size in response to retinal illumination can only  
26       account for a 1.2 log unit change in sensitivity to light. Older people tend to have smaller  
27       pupils under comparable conditions.

1           2. *Neural Adaptation.* This is a fast (less than one (1 s) second) change in  
2 sensitivity produced by synaptic interactions in the visual system. Neural processes  
3 account for virtually all the transitory changes in sensitivity of the eye where cone  
4 photopigment bleaching has not yet taken place (discussed below) – in other words, at  
5 luminance values commonly encountered in electrically lighted environments, below  
6 about 600 cd/m<sup>2</sup>. Because neural adaptation is so fast and is operative at moderate light  
7 levels, the sensitivity of the visual system is typically well adjusted to the interior scene.  
8 Only under special circumstances in interiors, such as glancing out a window or directly  
9 at a bright light source before looking back at a task, will the capabilities of rapid neural  
10 adaptation be exceeded. Under these conditions, and in situations associated with  
11 exteriors, neural adaptation will not be completely able to handle the changes in  
12 luminance necessary for efficient visual function.

13           3. *Photochemical Adaptation.* The retinal receptors (rods and cones) contain  
14 pigments which, upon absorbing light energy, change composition and release ions which  
15 provide, after processing, an electrical signal to the brain. There are believed to be four  
16 photopigments in the human eye, one in the rods, and one each in the three cone types.  
17 When light is absorbed, the pigment breaks down into an unstable aldehyde of vitamin A  
18 and a protein (opsin) and gives off energy that generates signals that are relayed to the  
19 brain and interpreted as light. In the dark, the pigment is regenerated and is again  
20 available to receive light. The sensitivity of the eye to light is largely a function of the  
21 percentage of unbleached pigment. Under conditions of steady brightness, the  
22 concentration of photopigment is in equilibrium; when the brightness is changed, pigment  
23 is either bleached or regenerated to reestablish equilibrium. Because the time required to  
24 accomplish the photochemical reactions is a finite, change in the sensitivity lag behind  
25 the stimulus changes. The cone system adapts much more rapidly than does the rod  
26 system; even after exposure to high levels of brightness, the cones will regain nearly  
27 complete sensitivity in ten (10 min) minutes – twelve (12 min) minutes, while the rods  
28 will require sixty (60 min) minutes (or longer) to fully dark-adapt.

1           4. *Transient Adaptation.* Transient adaptation is a phenomenon associated with  
2 reduced visibility after viewing a higher or lower luminance than that of the task. If  
3 recovery from transient adaptation is fast (less than one (1 s) second), neural processes  
4 are causing the change. If recovery is slow (longer than one (1 s) second), some changes  
5 in the photopigments have taken place. Transient adaptation is usually insignificant in  
6 interiors, but can be a problem in brightly lighted interiors or exteriors where  
7 photopigment bleaching has taken place. The reduced visibility after entering a dark  
8 movie theater from the outside on a sunny day is an illustration of this latter effect.

#### 9 10 SUMMARY

11           The present invention is a balanced blue spectrum therapy lighting fixture. The  
12 lighting fixture comprises a light source and a mixture of blue light and white light within  
13 the light source having a range between approximately 90% 420 – 490 nm blue light and  
14 approximately 10% white light to approximately 10% 420 – 490 nm blue light and  
15 approximately 90% white light.

16           The present invention further includes a method for creating balanced blue  
17 spectrum therapy lighting. The method comprises providing a light source and mixing  
18 blue light and white light having a range between approximately 90% 420 – 490 nm blue  
19 light and approximately 10% white light to approximately 10% 420 – 490 nm blue light  
20 and approximately 90% white light.

#### 21 22 BRIEF DESCRIPTION OF THE DRAWINGS

23           FIG. 1 is an elevational view illustrating a fluorescent bulb embodiment of the  
24 balanced blue spectrum therapy lighting, constructed in accordance with the present  
25 invention;

26           FIG. 2 is an exploded perspective view illustrating the balanced blue spectrum  
27 therapy lighting, constructed in accordance with the present invention;

1           FIG. 3 is an elevational view illustrating a fluorescent tube embodiment of the  
2 balanced blue spectrum therapy lighting, constructed in accordance with the present  
3 invention; and

4           FIG. 4 is sectional view illustrating an embodiment of the balanced blue spectrum  
5 therapy lighting, constructed in accordance with the present invention, with an after-glow  
6 phosphor undercoat.

7  
8           DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

9           As illustrated in FIGS. 1 – 3, balanced blue spectrum therapy lighting, indicated  
10 generally at 10, could be any type of light source that incorporates 420 – 490 nm blue  
11 light 12 with a white light 14. White light 14 is often referred to as cool white, warm  
12 white, daylight, or scotopic/photopic light. For this discussion the inventors of the  
13 present application define white light 14 as light with a correlated color temperature range  
14 of 2,500 – 10,000 degrees Kelvin and blue light 12 as light with a wavelength range of  
15 420 – 490 nm.

16           The benefit of the 420 – 490 nm blue light 12 is melatonin regulation, but the blue  
17 light 12 alone is a light source that may be difficult to work and/or read under. While  
18 using this blue light source, if a person looks away, for example, out a window or into  
19 another room which is not illuminated by the same blue light source, the surroundings  
20 often appear extremely yellow and depth perception may be distorted; this is commonly  
21 called visual chaos. Also, in some cases a person's equilibrium may be disturbed. This is  
22 because the blue light 12 saturates the rods of the eye and the person's color perception  
23 mechanism did not have time to adapt to the consequences of the color spectra of the  
24 different light sources, in this case the blue light source and the daylight outside the  
25 window. The blue light 12 may be balanced by adding white light, thereby mitigating the  
26 negative effects of the blue light 12 while still experiencing the benefits of the blue light  
27 melatonin regulation; this is the intention of balanced blue spectrum therapy lighting 10  
28 of the present invention.

1           As illustrated in FIG. 1, a balanced blue spectrum therapy lighting fixture 16  
2 constructed in accordance with the present invention could contain an array of fluorescent  
3 bulbs or L.E.D.'s, some blue 12 and some white 14. For example, a compact fluorescent  
4 PL-type bulb, also called a Biac bulb, could have one side emitting blue light 12 and one  
5 side emitting white light 14. This would be a single bulb that emits a balanced light.  
6 When the bulb is manufactured, first one half of the bulb would be filled with the 420 -  
7 490 nm blue phosphor and baked, then the other side would be filled with white phosphor  
8 and baked. The various amounts of each blue and white would be balanced appropriately  
9 for each specific application. The range can go from 90% 420 – 490 nm blue light 12 and  
10 10% white light 14, to only 10% blue light 12 and 90% white light 14 depending on the  
11 application. The preferred ratio is 50% blue light 12 and 50 % white light 14.

12           A balanced blue spectrum therapy lighting fixture 10 constructed in accordance  
13 with the present invention can be adjustable with a switching mechanism, either  
14 electronic or mechanical, or even activated by radio frequency switching so that a person  
15 can adjust the blue and white scotopic/photopic light levels, thereby affecting their  
16 melatonin levels as desired.

17           As illustrated in FIG. 3, color sleeves 18 over a light source could provide  
18 balanced blue spectrum therapy lighting 10 as described and claimed herein. The color  
19 sleeves 18 could be adjustable depending on the application and the melatonin levels or  
20 visual acuity desired.

21           The balanced blue spectrum therapy lighting 10 of the present invention can be  
22 incorporated into fiber optics by making one fiber for blue light 12 and one fiber for white  
23 light 14.

24           As illustrated in FIG. 4, the balanced blue spectrum therapy lighting 10 of the  
25 present invention can be combined with an after-glow phosphor undercoat 20 for  
26 applications that require emergency lighting.

27  
28 Example Formula for Preferred Scotopic Phosphor Blend:  
29

---

Preferred	Approx. %	Phosphor Chemical Composition	Phosphor Peak (nm)
40		SrO (P <sub>2</sub> O <sub>5</sub> B <sub>2</sub> O <sub>3</sub> ): Eu	478
22		Y <sub>2</sub> O <sub>3</sub> : Eu	611
20		La PO <sub>4</sub> : Co, Tb	544
18		Sr <sub>2</sub> P <sub>2</sub> O <sub>7</sub> : Eu	421
8		Ba Mg <sub>2</sub> Al <sub>16</sub> O <sub>27</sub> : Eu	450

Note: The Phosphor Peaks (nm) of 421, 450, and 478 in this example are scotopic and fall within the range as referred to melatonin regulates the circadian cycle of sleep.

Note: This phosphor blend above by itself has biological response to melatonin suppression and could be used for general lighting in any environment.

The preferred scotopic phosphor blend for visual acuity of the balanced blue spectrum therapy lighting 10 of the present invention is composed of combined commercially available phosphors to give light primarily in the 400 – 620 nm range, with the resulting emitted light spectrum favoring the human eye scotopic-response curve, peaking at approximately 500 nm. As light levels decrease, the human eye responds more to bluer light and less to yellow/red light. As light levels decrease, the human eye also loses transmission of blue light. With age, the eye also loses transmission of blue light and therefore benefits from more blue-light energy. The intent of a scotopic phosphor blend of the present invention is to address both of these conditions with a phosphor that enhances human vision. In addition, the phosphor combination is balanced to produce a good Color Rendering Index (CRI) for photopic vision. Preferably, this number is eighty-five (85) or greater to allow for very good color differentiation; however, a blend containing lower CRI will still provide excellent visualization for tasks such as reading, which require no color sensitivity.

1           The preferred scotopic phosphor blend for melatonin regulation is particularly rich  
2 in the scotopic spectrum (approximately between 420 – 550 nm) of light. At  
3 approximately 420 nm the melatonin reaction starts and at approximately 550 nm the  
4 melatonin reaction ends. The benefit of these wavelengths of light (enhanced blue  
5 energy) is that it can reduce the output of melatonin in the human body. Melatonin  
6 regulates the circadian cycle of sleep. The preferred scotopic phosphor blend of the  
7 present invention not only balances out the negative affects of the 420 – 490 nm blue  
8 light spectrum but also contributes to melatonin reduction and can be adjusted as future  
9 research dictates. As of now, the range between 420 – 490 nm shows the greatest results  
10 for melatonin regulation. The blend or mixture in the balanced blue spectrum therapy  
11 lighting 10 of the present invention is rich in this area with peaks at 478 nm, 450 nm, and  
12 421 nm. The scotopic blue spectrum blended bulbs are intended for installation in work  
13 environments such as in a submarine or an engine room of a boat where there is a lack of  
14 sunlight and where it is critical that the worker remain awake and alert. Therefore, the  
15 worker will have lower melatonin levels and a better chance to remain awake and alert,  
16 and also their eyes would be scotopically stimulated and ready to react to emergency low  
17 light situations of an afterglow blend. This scotopic phosphor blend could theoretically  
18 be used as light therapy for S.A.D. (Seasonal Affective Disorder) and be therapeutic in a  
19 low light environment such as a submarine along with its emergency light qualities.

20  
21 **Balanced Blue Spectrum Therapy Lighting** 10 of the present invention could be any  
22 type of light source that incorporates blue light 12 (light with a wavelength range of 420 –  
23 490 nm) with a white light 14 (light with a correlated color temperature range of 2,500 –  
24 10,000 degrees Kelvin). The blue light 12 can be balanced by adding white light 14  
25 thereby mitigating the negative visual and physiological effects of the blue light 12 while  
26 still experiencing the benefits of the blue light melatonin regulation; this is the intention  
27 of balanced blue spectrum therapy lighting 10 of the present invention.



1 **Visual acuity:** The preferred balanced white light phosphor blend of the present  
2 invention is composed of combined commercially available phosphors to give light  
3 primarily in the 400 – 620 nm range, with the resulting emitted light spectrum favoring  
4 the human eye scotopic-response curve, peaking at about 500 nm. It is further noted that  
5 a white light phosphor blend with a peak of 550 nm is also very acceptable. As light  
6 levels decrease, the human eye responds more to bluer light (scotopic) and less to  
7 yellow/red light (photopic). As light levels decrease, the human eye also loses  
8 transmission of blue light. With age, the eye also loses transmission of blue light and  
9 therefore benefits from more blue-light energy. The intent of a scotopic phosphor blend  
10 is to address both of these conditions with a phosphor that enhances human vision. In  
11 addition, the phosphor combination is balanced to produce a good Color Rendering Index  
12 (CRI) for photopic vision. Preferably, this number is 85 or greater to allow for very good  
13 color differentiation; however, a blend containing lower CRI will still provide excellent  
14 visualization for tasks such as reading, which require little color sensitivity.

15  
16 **Correction of negative perception of scotopic light:** Conventional scotopic 420 – 490  
17 nm blue lamps can produce certain problems: they visually distort skin tones and they  
18 may cause headaches and nausea. This balanced blue spectrum therapy lighting 10 of the  
19 present invention corrects the color to inhibit the common negative response by the public  
20 and eliminate the problems associated with conventional blue scotopic lamps.

21  
22 **Kelvin temperature:** The Kelvin correlated color temperature in the higher end of the  
23 scotopic to photopic ratio spectrum can range between 5,000 °K and 10,000 °K. The  
24 inventors of the present application have found the correlated color temperature 7,500 °K  
25 super daylight range with a 2.47 scotopic to photopic ratio to be nominally rich in  
26 scotopic eye response and a superior complimentary match for the 420 – 490 scotopic  
27 blue phosphor. Note: it is critical that the highest scotopic to photopic ratio be obtained.  
28 White light with a correlated color temperature between 2,500 °K and 10,000 °K provides  
29 a usable balance to the blue light.

**Addition of a UV component:** The addition of a UV component to create a full spectrum natural light with UVA/B balance can be added or adjusted for different applications without changing the effectiveness of this scotopic blend.

**Example Formula for Preferred Scotopic Phosphor Blend:**

---

Preferred Approx. %	Phosphor Chemical Composition	Phosphor Peak (nm)
40	SrO (P <sub>2</sub> O <sub>5</sub> B <sub>2</sub> O <sub>3</sub> ): Eu	478
22	Y <sub>2</sub> O <sub>3</sub> : Eu	611
20	La PO <sub>4</sub> : Co, Tb	544
18	Sr <sub>2</sub> P <sub>2</sub> O <sub>7</sub> : Eu	421
8	Ba Mg <sub>2</sub> Al <sub>16</sub> O <sub>27</sub> : Eu	450

---

Note: The phosphor peaks (nm) of 421, 450, and 478 in this example are scotopic and fall within the range as referred to melatonin regulates the circadian cycle of sleep.

Note: This phosphor blend above by itself has biological response to melatonin suppression and could be used for general lighting in any environment.

**Preferred Scotopic Phosphor Blend for Visual Acuity:** The preferred scotopic phosphor blend is composed of combined commercially available phosphors to give light primarily in the 400 – 620 nm range, with the resulting emitted light spectrum favoring the human eye scotopic-response curve, peaking at approximately 500 nm. As light levels decrease, the human eye responds more to bluer light and less to yellow/red light. As light levels decrease, the human eye also loses transmission of blue light. With age, the eye also loses transmission of blue light and therefore benefits from more blue light

1 energy. The intent of a scotopic phosphor blend is to address both of these conditions  
2 with a phosphor that enhances human vision. In addition, the phosphor combination is  
3 balanced to produce a good Color Rendering Index (CRI) for photopic vision. Preferably,  
4 this number is eighty-five (85) or greater to allow for very good color differentiation;  
5 however, a blend containing lower CRI will still provide excellent visualization for tasks  
6 such as reading, which require no color sensitivity.

7  
8 **Preferred Scotopic Phosphor Blend for Melatonin Regulation:** The preferred  
9 scotopic phosphor blend for melatonin regulation is particularly rich in the scotopic  
10 spectrum (approximately between 420 – 550 nm) of light. At approximately 420 nm the  
11 melatonin reaction starts and at approximately 550 nm the melatonin reaction ends. The  
12 benefit of these wavelengths of light (enhanced blue energy) is that it can reduce the  
13 output of melatonin in the human body. Melatonin regulates the circadian cycle of sleep.  
14 The preferred scotopic phosphor blend of the present invention not only balances out the  
15 negative affects of the 420 – 490 nm blue light spectrum but also contributes to melatonin  
16 reduction and can be adjusted as future research dictates. As of now the range between  
17 420 – 490 nm shows the greatest results for melatonin regulation. The blend of the  
18 present application is rich in this area with peaks at 478 nm, 450 nm, and 421 nm. The  
19 scotopic blue spectrum blended bulbs are intended for installation in work environments  
20 such as in a submarine or an engine room of a boat where there is a lack of sunlight and  
21 where it is critical that the worker remain awake and alert. Therefore, the worker will  
22 have lower melatonin levels and a better chance to remain awake and alert, and also their  
23 eyes would be scotopically stimulated and ready to react to emergency low light  
24 situations. This scotopic phosphor blend could theoretically be used as light therapy for  
25 S.A.D. (Seasonal Affective Disorder) and be therapeutic in a low light environment such  
26 as a submarine along with its emergency light qualities.

27  
28 **Emergency response:** Human response time is critical in an emergency. Balanced blue  
29 spectrum therapy lighting 10 of the present invention can be combined with an after-glow

phosphor undercoat 20. These particular scotopic phosphor blends produce light that enhances the eye's ability to adapt to varying lower light levels, therefore photochemical adaptation and transient adaptation response times are quicker. Because the time required to accomplish photochemical reactions is a finite, change in the sensitivity lag behind the stimulus changes. The cone system adapts much more rapidly than does the rod system; even after exposure to high levels of brightness, the cones will regain nearly complete sensitivity in approximately ten (10 min) minutes to twelve (12 min) minutes, while the rods will require approximately sixty (60 min) minutes (or longer) to fully dark-adapt. These scotopic blends in fact places the eye in a state of emergency readiness because the eye is already operating under higher scotopic light levels therefore engaging the stimulation of the rod receptors in the eye. The amount of scotopic enhancement of these blends that can be adjusted determines the amount of increased or decreased dilation of the pupil and engagement of the eye's rods. The amount of dilation and rod receptor stimulation under this scotopic blend prepares the eye to respond to the lower light levels of the after-glow phosphor blend which is primarily scotopic light and has a low light response curve of approximately 500 nm when the lamp power is turned off. Therefore the eye's photochemical adaptation and transient adaptation response times are quicker. Therefore human response time is critically reduced in an emergency. Scotopic illuminant predicts pupil size and has been demonstrated in several studies. The after-glow light output will continue for a period of time after power is cut off, the bulb is broken, and gasses released; and even the pieces on the floor will continue to emit light, therefore maximizing this emergency lighting bulb to its greatest potential. The bulb, when charged can be removed from the fixture. The bulb will continue to glow and can be used as a portable emergency light source.

**Energy efficiency:** A lamp containing these scotopic rich phosphor blend needs two-thirds ( $2/3$ ) the power to achieve the same visual acuity as photopic lighting. Less bulbs use less power, one-third ( $1/3$ ) less, that way a submarine or boat or military installation can use its electrical resources for offense or defense. These phosphor blends are critical

1 as to application of use of energy in a critical situation such as a submarine or military  
2 installation where the amount of bulbs and wattage can be reduced with the use of these  
3 scotopic phosphor blends, therefore electrical power can be diverted to more critical uses  
4 such as offense or defense. Also, the power can be shut off to the lights and they still  
5 have emergency lighting leaving extra power for emergency use. Scotopic light usage  
6 and reduction of energy used is well documented. The eye has to work less hard to  
7 achieve the same visual acuity. In a submarine, an engine room on a boat, or a building it  
8 is critical that power consumption be used for defense or offense rather than for lighting.  
9 Therefore the use of scotopic rich light is of great importance. Lamps with combinations  
10 of these scotopic blends and after-glow phosphor can be used in remote locations of any  
11 building under emergency situations where power is disconnected.

12  
13 **Glare on monitors:** One of the side effects of fluorescent or general photopic lighting is  
14 glare on monitors such as computers or other instrumentation. The balanced blue  
15 spectrum therapy lighting 10 of the present invention reduces glare, increases visual  
16 acuity, and increases black and white contrast. The scotopic blend has a lower lumen  
17 output therefore reducing glare on the monitor screen. Approximately one-third (1/3) to  
18 one-half (1/2) less lumens as in regular fluorescent lighting are needed for the same visual  
19 acuity. Typically L.E.D.'s have a lower lumen output than fluorescent lamps, so L.E.D.'s  
20 that operate in the scotopic range would have less glare on monitors. The function of this  
21 scotopic blend is to increase the amount of perceived light entering the human eye.

22  
23 **Pilot room on boat or airplane:** Side effects of nighttime navigation include the  
24 problem of reading under light to see charts or instrumentation and then having to look  
25 out into darkness, and also becoming drowsy and falling asleep. This is another example  
26 of photochemical adaptation and transient adaptation response times. With the scotopic  
27 balanced blue spectrum therapy lighting blend 10 of the present invention, the pilot could  
28 read or perform tasks and look out into darkness with minimal effect on his or her visual  
29 adaptation, and could also turn the brighter scotopic light off and still have a background

1 blue illumination for moving about the cabin. As an example, the standard procedure  
2 when using a periscope on a submarine is to turn off the bright lighting and turn on a  
3 photopic red light in order to darken the room. This balanced blue spectrum blend of the  
4 present invention would be applicable in this situation where the scotopic light would be  
5 the normal operating light and the blue spectrum therapy lighting would function to lower  
6 the interior light level when using the periscope. Another option is to modify this  
7 scotopic phosphor blend to be in the blue range for a bulb that could replace the photopic  
8 red light currently turned on when the periscope is being used. Furthermore, the blue  
9 range would be better than the photopic red light and could possibly be used as a primary  
10 light source for when the periscope is being used rather than the photopic red that is being  
11 used now. This scotopic blue blend would also benefit pilots by regulating melatonin  
12 stimulus as discussed. Falling asleep is a well-documented problem for nighttime  
13 navigators. In the event of a catastrophic power failure we could add an after-glow  
14 phosphor undercoat and their eyes would be ready to see in darkness and the illumination  
15 would allow the pilot to continue to read charts or perform simple tasks because the eyes  
16 would already have the rods engaged and ready to see in the lower light.

17  
18 **Compact Fluorescent PL-Type Bulb:** A compact fluorescent PL-type bulb 16, also  
19 called a Biax bulb, could have one side emitting blue light 12 and one side emitting white  
20 light 14. This would be a single bulb 16 that emits a balanced light. When the bulb 16 is  
21 manufactured, first one half of the bulb 16 would be filled with the 420 – 490 nm blue  
22 phosphor and baked, then the other side would be filled with white phosphor and baked.  
23 See FIG. 1.

24  
25 **L.E.D. Application:** A blue L.E.D. light may be balanced by adding white LED light.  
26 The L.E.D. array can be configured with various amounts of each blue and white  
27 L.E.D.'s, balanced appropriately for each specific application. The range can go from  
28 90% 420 – 490 nm blue L.E.D.'s and 10% white L.E.D.'s, to only 10% blue L.E.D.'s and  
29 90% white L.E.D.'s depending on the application. The L.E.D. Luminaire may be

adjustable with a switching mechanism, either electronic or mechanical, or even activated by radio frequency so that a person can adjust the blue and white scotopic/photopic light levels, thereby affecting their melatonin levels as desired. See FIG. 2.

**Arrays:** A balanced blue spectrum therapy lighting fixture 10 could contain an array of fluorescent bulbs or L.E.D.'s, some blue and some white. The various amounts of each blue and white would be balanced appropriately for each specific application. The range can go from 90% 420 – 490 nm blue and 10% white, to only 10% blue and 90% white depending on the application. The preferred ratio is 50% blue light 12 and 50 % white light 14.

**Switching Mechanism:** A balanced blue spectrum therapy lighting fixture 16 may be adjustable with a switching mechanism, either electronic or mechanical, or even activated by radio frequency switching so that a person can adjust the blue and white scotopic/photopic light levels, thereby affecting their melatonin or visual acuity levels as desired.

**Color Sleeves:** Color sleeves 18 and/or transparencies in the range of 420 – 490 nm blue spectrum over a light source could provide balanced blue spectrum therapy lighting. The color sleeves 18 could be slipped on a fluorescent light and/or any light source including incandescent and adjust the blue to white ratio depending on the application and the melatonin levels desired. See FIG. 3.

**Fiber Optics:** Balanced blue spectrum therapy lighting can be incorporated into fiber optics by making one fiber for blue light 12 and one fiber for white light 14 in any combination ratio desired.

**After-Glow Phosphor Undercoat:** The balanced blue spectrum therapy lighting 10 can be combined with an after-glow phosphor undercoat 20 for applications that require emergency lighting. The after-glow phosphor undercoating 20 is put in a fluorescent tube

1 first, under either the blue light phosphor or the white light phosphor or both. When  
2 power is cut to the fluorescent bulb the after-glow phosphor blend still continues to emit  
3 visual light for emergency situations. See FIG. 4.

4  
5 **Variance of use:** There are many types of lamps and fixtures that could incorporate  
6 balanced blue spectrum therapy lighting. This balanced blue spectrum blend could be put  
7 into a wide variety of fluorescent tubes and bulbs. Incandescent bulbs could be tinted to  
8 different ratios, an example being a typical bulb could be tinted one half blue and one half  
9 no tint. Another example would be where the whole bulb is tinted blue and it is put in a  
10 light fixture with another bulb that's not tinted and the ratio could be adjusted depending  
11 on the visual acuity and melatonin regulation desired. These scotopic bulbs could fit into  
12 existing fluorescent lighting fixtures for general luminance. These could also be put into  
13 any location where predictable low light happens frequently such as in New York City  
14 subways.

15  
16 In sum, the balanced blue spectrum therapy lighting 10 of the present invention  
17 could be any type of light source that incorporates 420 – 490 nm blue light 12 with a  
18 white light 14. White light 12 is often referred to as cool white, warm white, daylight, or  
19 scotopic/photopic light. In the present application, white light 14 is defined as light with  
20 a correlated color temperature range of 2,500 – 10,000 degrees Kelvin, and blue light 12  
21 is defined as light with a wavelength range of 420 – 490 nm.

22 The benefit of the 420 – 490 nm blue light 12 is melatonin regulation, but the blue  
23 light 12 alone is a light source that may be difficult to work and/or read under. While  
24 using this blue light source, if a person looks away, for example out a window or into  
25 another room which is not illuminated by the same blue light source, the surroundings  
26 may appear extremely yellow and depth perception may be distorted; this is commonly  
27 called visual chaos. Also, in some cases a person's equilibrium may be disturbed. This is  
28 because the blue light 12 saturates the rods of the eye and the person's color perception  
29 mechanism did not have time to adapt to the consequences of the color spectra of the



1 different light sources, in this case the blue light source and the daylight outside the  
2 window. With the present invention, the blue light 12 can be balanced by adding white  
3 light 14, thereby mitigating the negative effects of the blue light 12 while still  
4 experiencing the benefits of the blue light melatonin regulation; this is the intention of  
5 balanced blue spectrum therapy 10 lighting of the present invention.

6  
7 The foregoing exemplary descriptions and the illustrative preferred embodiments  
8 of the present invention have been explained in the drawings and described in detail, with  
9 varying modifications and alternative embodiments being taught. While the invention  
10 has been so shown, described and illustrated, it should be understood by those skilled in  
11 the art that equivalent changes in form and detail may be made therein without departing  
12 from the true spirit and scope of the invention, and that the scope of the present invention  
13 is to be limited only to the claims except as precluded by the prior art. Moreover, the  
14 invention as disclosed herein, may be suitably practiced in the absence of the specific  
15 elements which are disclosed herein.